Abstract:In this study a new chitosan (CS) derivative, galactosylated chitosan (GC), was synthesized and used to prepare norcantharidin-associated GC nanoparticles (NCTD-GC NPs) by taking advantage of the ionic cross-linkage between the molecules of the anti-hepatocarcinoma medicine NCTD and of the GC as carrier. NCTD-GC NPs were obtained with average particle size of 118.68 +/- 3.37 nm, entrapment efficiency of 57.92 +/- 0.40%, and drug-loading amount of 10.38 +/- 0.06%. Several important factors influencing the entrapment efficiency, drug-loading amount, and particle size of NCTD-GC NPs were studied. The characteristics of sustained and pH-sensitive release of NCTD from NCTD-GC NPs in vitro were studied. In addition, in vitro cellular uptake and cytotoxicity of nanoparticles to hepatoma cell lines SMMC-7721 and HepG2 were also investigated. In vitro, and compared to CS-based NCTD-CS NPs, NCTD-GC NPs demonstrated satisfactory compatibility with hepatoma cells and strong cytotoxicity against hepatocellular carcinoma cells. In vivo antitumor activity of NCTD-GC NPs was evaluated in mice bearing H22 liver tumors. NCTD-GC NPs displayed tumor inhibition effect in mice, better than either the free NCTD or the NCTD-CS NPs. As a hepatocyte-targeting carrier, GC NPs are potentially promising for clinical applications.From the Clinical Editor: In this paper, a galactosylated chitosan (GC), was synthesized and norcantharidin (NCTD)-associated galactosylated chitosan nanoparticles (NCTDGC NPs) were generated by coupling NCTD - an anti-hepatocarcinoma drug - and GC as carrier. Compared to chitosan nanoparticles, NCTD-GC-NPs demonstrated satisfactory compatibility with hepatoma cells and strong cytotoxicity against the cells. (C) 2010 Elsevier Inc. All rights reserved.

Preparation and in Vitro Antineoplastic Activity of Norcantharidi N-Associated Galactosylated Chitosan Nanoparticles

Study on an Active Hepatocyte-Targeting Antineoplastic Activity of Norcantharidin-Loaded Galactosylated Chitosan Nanoparticles

Preparation of Norcantharidin N-galaetosylated Chitosan Nanoparticles and Its Characteristics

Norcantharidin-Associated Galactosylated Chitosan Nanoparticles For Hepatocyte-Targeted Delivery

Preparation, Characterization and Drug Release in Vitro of Galactosylated Chitosan-Graft-PEG Nanoparticles

Study on Absorption Mechanism and Anti-tumor Pharmacodynamics in Mice of Norcantharidin Loaded N-Galactosylated Chitosan Nanoparticles

Novel Norcantharidin-Loaded Liver Targeting Chitosan Nanoparticles to Enhance Intestinal Absorption

Preparation and pharmacological evaluation of norcantharidin-conjugated carboxymethyl chitosan in mice bearing hepatocellular carcinoma.

Characterization and in Vitro Release of Chitosan Nanoparticles Loading Norcantharidin

Studies on Anti-Hepatocarcinoma Effect, Pharmacokinetics and Tissue Distribution of Carboxymethyl Chitosan Based Norcantharidin Conjugates.

Synthesis and in vitro cellular evaluation of novel anti-tumor norcantharidin-conjugated chitosan derivatives

Study on Preparation and in Vitro Release of Norcantharidin-Loaded Chitosan Microspheres

Primary in vitro and in vivo evaluation of norcantharidin-chitosan/poly (vinyl alcohol) for cancer treatment.

Galactosylated nanocrystallites of insoluble anticancer drug for liver-targeting therapy: an in vitro evaluation.

Investigation on Anticancer Activity of Nanoparticles Loaded Lactosyl-Norcantharidin

Preparation of a Novel Liver-Targeting Nanoparticle of Norcantharidin Derivative and Evaluation of Its Anti-Tumour Activity

Study on the Distribution and Liver Targeting of Norcantharidin Nanoparticles in Mice

Synthesis of Hepatocyte-Targeting Norcantharidin Prodrug and Preparation of Its Nanoparticles

Preparation and characterization of norcantharidin liposomes modified with stearyl glycyrrhetinate.

Optimization of Norcantharidin-Loaded Chitosan Microspheres Preparation with Central Composite Design and Response Surface Methodology for Hepatocellular Chemoembolization

N-trimethyl chitosan nanoparticle-encapsulated lactosyl-norcantharidin for liver cancer therapy with high targeting efficacy.